Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer

BACKGROUND: Programmed cell death 1 ligand 1(PD-L1) is overexpressed in many tumors. The radionuclide-labeled anti-PD-L1 monoclonal antibody can be used for imaging and therapy of PD-L1 overexpressing cancer. Here, we described (131)I-labeled Atezolizumab ((131)I-Atezolizumab, targeting PD-L1) as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Linhan, Zhao, Sheng, Jiang, Huijie, Zhang, Rongjun, Zhang, Mingyu, Pan, Wenbin, Sun, Zhongqi, Wang, Dandan, Li, Jinping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Preliminary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616992/
https://www.ncbi.nlm.nih.gov/pubmed/36307610
http://dx.doi.org/10.1186/s13550-022-00939-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616992/
https://www.ncbi.nlm.nih.gov/pubmed/36307610
http://dx.doi.org/10.1186/s13550-022-00939-2

Ejemplares similares